Donepezil

Generic Name
Donepezil
Brand Names
Adlarity, Aricept, Namzaric
Drug Type
Small Molecule
Chemical Formula
C24H29NO3
CAS Number
120014-06-4
Unique Ingredient Identifier
8SSC91326P
Background

In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...

Indication

Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...

Associated Conditions
Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
Associated Therapies
-
Clinical Trials
Related News

Brain Imaging and Mental Disorders of Aging Intervention

Phase 4
Completed
Conditions
Cognition Disorders
Interventions
Drug: donepezil
Drug: Placebo
First Posted Date
2005-12-20
Last Posted Date
2008-08-29
Lead Sponsor
National Institute on Aging (NIA)
Target Recruit Count
64
Registration Number
NCT00267163
Locations
🇺🇸

UCLA, The Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

Phase 4
Completed
Conditions
Alzheimer's Disease
First Posted Date
2005-10-03
Last Posted Date
2011-04-01
Lead Sponsor
Eisai Inc.
Target Recruit Count
100
Registration Number
NCT00230568
Locations
🇺🇸

Clinical Research Center, Jenkintown, Pennsylvania, United States

🇺🇸

University of New Mexico School of Medicine, Department of Psychiatry, Albuquerque, New Mexico, United States

🇺🇸

21st Century Neurology, Phoenix, Arizona, United States

and more 30 locations

Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

Phase 4
Completed
Conditions
Cerebrovascular Accident
Interventions
Drug: Donepezil
Drug: Galantamine
First Posted Date
2005-09-28
Last Posted Date
2017-12-11
Lead Sponsor
University of Pittsburgh
Target Recruit Count
40
Registration Number
NCT00227994
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

An Open-Label Trial of Donepezil in Fragile X Syndrome

Phase 1
Completed
Conditions
Fragile X Syndrome
Interventions
Drug: donepezil
First Posted Date
2005-09-22
Last Posted Date
2012-12-13
Lead Sponsor
Stanford University
Target Recruit Count
10
Registration Number
NCT00220584
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Prevention of Postoperative Delirium With Donepezil

Phase 4
Completed
Conditions
Cognitively Normal Elderly Individuals
First Posted Date
2005-09-22
Last Posted Date
2011-09-14
Lead Sponsor
Technical University of Munich
Target Recruit Count
37
Registration Number
NCT00220896
Locations
🇩🇪

Deps. of Psychiatry and Anaesthesiology, Tech. Universitaet Munich, Munich, Germany

Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial

Phase 4
Completed
Conditions
Stroke
Aphasia
First Posted Date
2005-09-20
Last Posted Date
2005-09-20
Lead Sponsor
Gabinete Berthier y Martínez
Target Recruit Count
30
Registration Number
NCT00196690
Locations
🇪🇸

Gabinete Berthier y Martínez, Malaga, Spain. Centro de Investigaciones Médico-Sanitarias (CIMES), UNiversity of Malaga, Malaga, Spain., Malaga, Spain

Donepezil Treatment of Psychotic Symptoms in Dementia Patients

First Posted Date
2005-09-19
Last Posted Date
2010-09-08
Lead Sponsor
Beersheva Mental Health Center
Target Recruit Count
80
Registration Number
NCT00190021
Locations
🇮🇱

Beersheva Mental Health Center, Beersheva, Israel

Donepezil in the Prevention of Post-Operative Cognitive Decline

Phase 4
Completed
Conditions
Postoperative Complications
Delirium
First Posted Date
2005-09-16
Last Posted Date
2008-03-03
Lead Sponsor
Pfizer
Target Recruit Count
30
Registration Number
NCT00182845
Locations
🇺🇸

University Hospital, Clarian Health Partners, Indianapolis, Indiana, United States

Donepezil in Preventing Delirium in Hospitalized Elderly

Phase 4
Completed
Conditions
Postoperative Complications
Delirium
First Posted Date
2005-09-16
Last Posted Date
2008-03-03
Lead Sponsor
Indiana University Health
Target Recruit Count
30
Registration Number
NCT00182884
Locations
🇺🇸

Methodist Hospital, Clarian Health Partners, Indianapolis, Indiana, United States

Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

Phase 3
Terminated
Conditions
Dementia, Vascular
Dementia, Mixed
Interventions
Drug: Donepezil
First Posted Date
2005-09-15
Last Posted Date
2015-03-24
Lead Sponsor
Pfizer
Target Recruit Count
149
Registration Number
NCT00174382
Locations
🇨🇦

Pfizer Investigational Site, Regina, Saskatchewan, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy